Catalyst Pharmaceuticals (CPRX) Common Equity (2010 - 2026)

Catalyst Pharmaceuticals' Common Equity history runs 17 years deep, the most recent figure standing at $1.0 billion for Q1 2026.

• Quarterly Common Equity rose 27.5% year-over-year to $1.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 billion (up 27.5% YoY) and the FY2025 annual result came in at $954.3 million, up 31.15% from the prior year.
• Common Equity was $1.0 billion for Q1 2026 at Catalyst Pharmaceuticals, up from $954.3 million in the prior quarter.
• Across five years, Common Equity topped out at $1.0 billion in Q1 2026 and bottomed at $220.2 million in Q1 2022.
• A 5-year average of $563.1 million and a median of $561.4 million in 2024 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity gained 23.27% — and 2024, when it surged 89.63%.
• Catalyst Pharmaceuticals' Common Equity stood at $300.4 million in 2022, then gained by 29.11% to $387.9 million in 2023, then soared by 87.59% to $727.6 million in 2024, then surged by 31.15% to $954.3 million in 2025, then grew by 6.12% to $1.0 billion in 2026.
• Business Quant data shows CPRX's Common Equity at $1.0 billion in Q1 2026, $954.3 million in Q4 2025, and $920.2 million in Q3 2025.